Vericel Corporation $VCEL Shares Acquired by Conestoga Capital Advisors LLC

Posted by Stanley Muller on Jul 2nd, 2026

Conestoga Capital Advisors LLC lifted its holdings in shares of Vericel Corporation (NASDAQ:VCEL – Free Report) by 9.3% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 2,463,312 shares of the biotechnology company’s stock after acquiring an additional 208,750 shares during the period. Vericel makes up approximately 1.6% of Conestoga Capital Advisors LLC’s investment portfolio, making the stock its 27th largest holding. Conestoga Capital Advisors LLC’s holdings in Vericel were worth $79,245,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Huntington National Bank raised its position in shares of Vericel by 51.3% in the 3rd quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 273 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Vericel during the 4th quarter worth approximately $27,000. Quarry LP purchased a new stake in Vericel during the 4th quarter worth approximately $31,000. Farther Finance Advisors LLC increased its stake in Vericel by 116.5% during the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 522 shares in the last quarter. Finally, Truvestments Capital LLC increased its stake in Vericel by 175.4% during the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 977 shares in the last quarter.

Vericel Stock Up 1.5%

Vericel stock opened at $45.15 on Thursday. The business’s 50-day moving average price is $36.69 and its 200 day moving average price is $35.95. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 107.50 and a beta of 1.06. Vericel Corporation has a 52 week low of $28.95 and a 52 week high of $46.62.

Vericel (NASDAQ:VCEL – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Vericel had a return on equity of 6.41% and a net margin of 7.35%.The company had revenue of $68.43 million during the quarter, compared to the consensus estimate of $63.68 million. During the same period in the previous year, the company posted ($0.23) earnings per share. Vericel’s revenue for the quarter was up 30.1% on a year-over-year basis. Equities analysts expect that Vericel Corporation will post 0.49 EPS for the current year.

Insider Activity

In related news, insider Jonathan Mark Hopper sold 10,000 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. Following the completion of the transaction, the insider directly owned 75,753 shares in the company, valued at $3,408,885. The trade was a 11.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jonathan Siegal sold 2,732 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $44.90, for a total transaction of $122,666.80. Following the completion of the transaction, the insider owned 886 shares of the company’s stock, valued at approximately $39,781.40. This represents a 75.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 47,732 shares of company stock valued at $2,084,167 in the last quarter. Company insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on VCEL shares. HC Wainwright reaffirmed a “buy” rating and issued a $64.00 price target on shares of Vericel in a report on Friday, May 8th. Truist Financial dropped their price objective on shares of Vericel from $48.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. Weiss Ratings raised Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Wall Street Zen lowered Vericel from a “buy” rating to a “hold” rating in a research note on Sunday, June 14th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $46.00 price target on shares of Vericel in a research report on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $52.50.

Read Our Latest Research Report on Vericel

About Vericel

(Free Report)

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.